IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence? to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI?, advanced analytics, the latest technologies and extensive domain expertise. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
iqvia stock price forecast
IQVIA Holdings’ estimated fair value is US$354 based on 2 Stage Free Cash Flow to Equity
Current share price of US$204 suggests IQVIA Holdings is potentially 42% undervalued
Analyst price target for IQV is US$250 which is 30% below our fair value estimate
Based on 22 Wall Street analysts offering 12 month price targets for IQVIA Holdings in the last 3 months. The average price target is $250.71 with a high forecast of $276.00 and a low forecast of $200.00. The average price target represents a 22.51% change from the last price of $204.64.
iqvia stock news
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences.
The healthcare and life sciences industries generate vast amounts of data, representing significant potential for AI-powered solutions. This collaboration between IQVIA and NVIDIA will help accelerate IQVIA Healthcare-grade AI?, enabling new levels of agentic automation of complex and time-consuming workflows across the therapeutic life cycle with the precision, scalability, and trust required by IQVIA’s customers. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. IQVIA Healthcare-grade AI? represents the company’s commitment to these principles.
The collaboration will combine IQVIA’s unparalleled information assets, analytics, and domain expertise, known as IQVIA Connected Intelligence?, with the NVIDIA AI Foundry service to help transform life science processes from R&D through commercialization. This work is poised to create new efficiencies, enable new operating models, and ultimately improve patient outcomes.